替吉奥联合奥沙利铂治疗晚期胃癌临床评价

目的：观察替吉奥胶囊联合奥沙利铂方案治疗晚期胃癌的临床疗效及不良反应。方法：38例晚期胃癌患者，替吉奥胶囊每天80mg／m^2，分2次，餐后口服，d1－d14；奥沙利铂130mg／m^2，静脉滴注3h，d1；28d为1个周期。按RECIST1．1标准评价客观疗效，按CTC—AE4．0评价不良反应。结果：38例患者均可评价疗效，其中CR2例（5．26％），PR12例（31．58％），SD15例（39．47％），PD9例（23．68％），RR36．84％，DCR76．31％，中位疾病进展时间（TTP）为7．9个月，中位生存期（MST）为1012个月。不良反应主要表现为骨髓抑制、消化道反应及外周神经毒性等。结论：替吉奥联合奥沙利铂方案治疗晚期胃癌的近期疗效较好，不良反应可以耐受，值得临床研究和进一步推广应用。

Clinical Evaluation of the Combination of S-1 and Oxaliplatin in the Treatment of Patients with Advanced Gastric Cancer

Objective： To evaluate the efficacy and toxicity of the combination regimen of S1 and oxaliplatin （ SOX ） in the treatment of patients with advanced gastric cancer.Method： A total of 38 patients with advanced gastric cancer were treated with SOX regimen.S-I was administered orally, 40 mg/ （ m^2 · d ）, bid, with a schedule of 14 days on and 7 days off, while oxaliplatin was administered i.v. （ 130 mg/m^2 ） on day 1.The regimen was repeated every 21 days.The efficacies and toxicities were evaluated with RECIST 1.1 and CTC-AE 4.0.Result： Of the 38 evaluable patients, there were 2 （ 5.26% ） complete remission （ CR ）, 12 （ 31.58% ） partial remission （ PR ）, 15 （ 39.47% ） stable disease （ SD ）, and 9 （ 23.68% ） progression disease （ PD ） .The overall response rate and the disease control rate （ DCR ） was 36.84% and 76.31%, respectively.The time to progression （ TIP ） was 7.9 months.The median survival time （ MST ） was 10.2 months.The major toxicities included myelosuppression, gastrointestinal reaction and peripheral nenrotoxicity.Conclusion： The combination of S-1 and oxaliplatin is effective and tolerable in the treatment of patients with advanced gastric cancer and is worthy of further evaluation.